- Final NDA submission nearing completion and will be filed in the next two weeks
- Launch readiness on track for expected launch in H12027, subject to FDA approval
- Data from two positive Phase 3 trials reinforce COMP360's unique and highly differentiated profile of rapid onset and durability of effect with 52-week open label data from COMP005 showing notable added benefit from an additional COMP360 25 mg dose extending durability out to one year
- The Phase 3 data supports the belief that COMP360 has the potential to establish a new standard of care in TRD that can be life-changing for patients − moving beyond daily or frequent administration toward an option that could provide durable benefit with just a few treatments a year
- COMP360 expected to be a blockbuster opportunity with an estimated 4 million people in the U.S. living with TRD, a significantly underserved market where the only marketed medicine has captured
Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights
Summary by 6ix AI
Compass Pathways reported third quarter 2026 results and business updates. It said its final New Drug Application, the filing asking the US Food and Drug Administration (FDA) to approve COMP360 for treatment-resistant depression (TRD), was nearing completion as of November 3, 2026.
Key details
- The company said it expects to file the application within two weeks of its November 3, 2026 update.
- Compass Pathways says its launch preparations are on track for an expected launch in the first half of 2027, subject to FDA approval.
- The company says data from two Phase 3 (late-stage) trials it describes as positive show COMP360 has a rapid onset and a lasting effect.
- Compass Pathways says 52-week open-label data (patients and doctors knew the treatment given) from its COMP005 trial showed added benefit from an extra COMP360 25 mg dose, extending how long the effect lasted out to one year.
- The company estimates that 4 million people in the U.S. live with TRD.
What’s still pending
- The New Drug Application had not yet been filed as of November 3, 2026.
- Launch of COMP360 is subject to FDA approval; the company expects launch in the first half of 2027.
6ix AI wrote this summary from the release below and checked it against the release.
In the deck
Earlier from COMPASS Pathways
- New Joint Survey from Compass Pathways and the Depression and Bipolar Support Alliance Reveals the Lived Burden of Treatment-Resistant Depression on Patients and Caregivers
- Compass Pathways to Highlight Scientific Research and TRD Disease State Education Efforts at the 2026 Neuroscience Education Institute Fall Congress
- Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 2026
- Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026
- Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Later from COMPASS Pathways
- Compass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11th
- Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression
- Compass Pathways to Participate in Jefferies Global Healthcare Conference on November 18th and 19th
- Compass Pathways to Participate in 9th Annual Evercore Healthcare Conference on December 1
Follow COMPASS Pathways into a list and get an email when it puts out news.
Follow COMPASS Pathways